Nephrotic syndrome after treatment with pamidronate.
Markowitz
Glen S
GS
Department of Pathology, Columbia College of Physicians and Surgeons, New York, NY 10032, USA. vdd1@columbia.edu
Fine
Paul L
PL
D'agati
Vivette D
VD
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy; D009404:Nephrotic Syndrome / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology; D000077268:Pamidronate
D000970:Antineoplastic Agents; D004164:Diphosphonates; D000077268:Pamidronate